MOVEMENT DISORDERS REFERRAL FORM (A-I)

PHONE 888.370.1724 | **FAX** 877.645.7514



Remove above portion before faxing. Please complete the prescription form in its entirety and fax with secure cover sheet to the number above.

						-								
PATIENT INFORMATION														
Last Name	First Name	DOB			Gender	□M □F	F La	st 4 SSN		Prin	nary Lar	nguage		
Address				City					State			ZIP		
Email	Home Phone				Wo	rk Phone					Cell Pho	ne		
Primary Contact Method (check one) Cell Phone Home Ph	one [☐ Work Phone	T	ext 🗆 Eı	mail 🗆	Primar	y Caregiver	□ DC	NOT CON	ITACT			
Primary Caregiver/Alt Contact Name	(If applicable)		Alt Contac	ct Ema	il					Alt	Contact	Phone		
PRESCRIBER INFORMATION	1													
Name of Contact Sending Referral		Т	Γitle			Pr	referred	l Contact Me	thod (cl	neck one)	□Em	ail 🗆 Phone		Fax
Referral Contact Email					Office F	Phone				Office Fa	ax			
Practice / Facility Name					Prescri	ber Name	/ Spec	ialty						
Address					City					St	tate	Z	IP.	
Prescriber State License #	scriber State License # DEA #			NPI # Medicaid UPIN #						UPIN #				
	* Please includ	e a c	opv of the	e fro	nt and	back o	f ins	urance c	ard *					
CLINICAL INFORMATION - F														
Patient New to Therapy ☐ Naïve/New	w Start	□Existi	ng Treatment		Therapy Start Date Date of Next B					ext Bloc	ood Work			
Other/Concomitant Medications (ple	ase list)				Patient Height (cm/in): Weight (kg/lbs): D					Dat	ate Obtained:			
Allergies □ NKDA □ Drug Allergi	es (please list)													
	criber's Office	e list)												
ICD-10 Code ☐ G10: Hunt	ington's Disease		☐ G24.0°		ive Dyskine	esia		Description:						
PRESCRIPTION INFORMATION IN order for a brand name production your state-specific required la	ON - Please Escribe if re ct to be dispensed, the pres	criber	d by state must handw	law vrite "l	Brand Ne		or "Bi	rand Medic	ally Ne		cations			
MEDICATION	DOSE		DIRECTIONS									QTY		REFILLS
Austedo	☐ 6 mg Tablet ☐ 9 mg Tablet ☐ 12 mg Tablet (Note: For titration dosing, select all 3 strengths & appropriate quantity will be dispensed)		INITIAL TI 12 mg/day 18 mg/day 24 mg/day 30 mg/day	(6 mg (9 mg (12 mg (15 mg	BID) x Wee BID) x Wee g BID) x We g BID) x We	ek 1 ek 2 eek 3 eek 4						QS		0
			□ INITIAL TITRATION - Huntington's Disease Chorea • 6 mg/day x Week 1 • 12 mg/day (6 mg BID) x Week 2 • 18 mg/day (9 mg BID) x Week 3 • 24 mg/day (12 mg BID) x Week 4						QS		0			
		CONTINUING & SAMPLED PATIENTS (TD & HD CHOREA) Titrate weekly by 6 mg/day from current dose of mg/day to reach the dose selected below (select one): 24 mg/day (12 mg BID) 30 mg/day (15 mg BID) 42 mg/day (21 mg BID) 48 mg/day (21 mg BID) OR OR						dose						
□ Ingrezza	☐ 40 mg Tablet		INITIAL DOS										+	
L Higrezza	60 mg Tablet 80 mg Tablet		Initial Rx with 80 mg Maintenance Dose 40 mg by mouth once daily x7 days, then 80 mg by mouth once daily x 23 days							#7 (40 mg #23 (80 mg		0		
			MAINTENANCE DOSE: □ 40 mg by mouth once daily □ 60 mg by mouth once daily □ 80 mg by mouth once daily						#30 #30 #30					
Prescriber Signature	Da	nte	Other Rx					ature (where	e require	ed by state	· law)	Date		
DAW (Dispense as Written)		Date			Brand Nec	essary (m	nust hai	ndwrite)						

Note: The information contained in this document will become a legal prescription. Prescriber is to comply with his/her state specific Pharmacy and Medical Board guidelines such as e-prescribing, state specific prescription form, fax language, number of prescriptions allowed on a single prescription form, etc. If more than one page is required, make additional copies. Non-compliance with state specific requirements could result in outreach to the prescriber.

MOVEMENT DISORDERS REFERRAL FORM (J-Z)

PHONE 888.370.1724 | **FAX** 877.645.7514



Remove above portion before faxing. Please complete the prescription form in its entirety and fax with secure cover sheet to the number above.

<u> </u>					_						
PATIENT INFORMATION											
Last Name	First Name	DOB		Gender □ M	□F	Last 4 SSN		Primary La	nguage		
Address			City			s	tate		ZIP		
Email	Home Phone			Work Ph	one	<u> </u>		Cell Pho	one		
Primary Contact Method (check one	e) 🗆 Cell Phone 🗆 Home Pho	one 🗆 Work Phon	e □T	ext 🗆 Email	□ Pr	imary Caregiver	DO NOT	CONTACT			
Primary Caregiver/Alt Contact Name	e (If applicable)	Alt Conta	act Ema	il				Alt Contact	t Phone		
PRESCRIBER INFORMATION	N	<u>'</u>									
Name of Contact Sending Referral		Title			Pref	erred Contact Metho	d (check	one) 🗆 Em	nail 🗆 Phone	□ Fax	
Referral Contact Email				Office Phone	•		Offi	ce Fax			
Practice / Facility Name				Prescriber Name / Specialty							
Address			City State						ZI	P	
Prescriber State License # DEA #			NPI # Medicaid UPIN #								
	* Please include	e a copy of th	e fro	nt and hac	k of	insurance card					
CLINICAL INFORMATION - I				ne ana sac	κ ο,	msurance care					
				The survey Charle F			Data	of Nove Dis	l 14/ul-		
Patient New to Therapy Naïve/Ne		Existing Treatment						ate of Next Blood Work			
Other/Concomitant Medications (ple			Patient Height (cm/in): Weight (kg/lbs): Da						ate Obtained:		
	ies (please list)										
-	criber's Office										
	tington's Disease kinson's Disease	☐ G24.0 ☐ Other		ive Dyskinesia		Description:			_		
PRESCRIPTION INFORMATI	ON - Please Escribe if re	guired by state	law								
In order for a brand name produ	ct to be dispensed, the pres	criber must handv	write "l								
or your state-specific required la				alid prescript	ion fo	orm for writing con	trolled n	nedications			
MEDICATION	DOSE	DIRECTIONS							QTY	REFILLS	
☐ Kynmobi	☐ Titration Kit		Contact Kynmobi Kynnect at 1-844-596-6624 for more information. Place 1 film under the tongue, do not exceed doses per day.							0	
	MAINTENANCE DOSE: ☐ 10 mg SL film	Place 1 film									
	☐ 15 mg SL film ☐ 20 mg SL film								30-Day		
	☐ 25 mg SL film										
	□ 30 mg SL film										
☐ Neuromuscular Blocker / Botulinum Toxins	□ Botox □ 50 U □ 100 U □ 200 U		DIRECTIONS FOR USE (include frequency, minimum is 12 weeks; to be given by a prescriber in office, unless otherwise specified):								
	☐ Dysport ☐ 300 U ☐ 500 U										
	☐ Myobloc ☐ 2500 U ☐ 5000 U ☐ 1000	011		ction(s) – (specify site(s) and number of units per site):					Vials		
	☐ Xeomin		r Injectio								
	□ 50 U □ 100 U □ 200 U										
☐ Tetrabenazine	☐ 12.5 mg Tablet		N/TITR	ATION DOSE							
	☐ 25 mg Tablet	Week 1:							QS	0	
	☐ Patient has Genotype for CY	P2D6 Week 3:	Week 4:								
		MAINTENAN Sig:	NCE DO	SE:							
		1-13-									
Prescriber Signature	Da	te		Supervising Phy	ysician	Signature (where red	quired by	state law)	Date		
				Drand Na	n. /	et handwrite)					
DAW (Dispense as Written)		Date		Brand Necessar							

Note: The information contained in this document will become a legal prescription. Prescriber is to comply with his/her state specific Pharmacy and Medical Board guidelines such as e-prescribing, state specific prescription form, fax language, number of prescriptions allowed on a single prescription form, etc. If more than one page is required, make additional copies. Non-compliance with state specific requirements could result in outreach to the prescriber.